SCHEMBL10189274

SCHEMBL10189274

CSc1ccc(-c2csnc2-c2cc(C)c3c(c2)OCO3)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.36
GAA P10253 3/20 0.34
MAPT P10636 3/20 0.34
TP53 P04637 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
HSD17B10 Q99714 1/20 0.33
PTGS2 P35354 1/20 0.32
ALDH1A1 P00352 2/20 0.32
LMNA P02545 2/20 0.32
HPGD P15428 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
EDNRA P25101 1/20 0.32
MAOB P27338 1/20 0.31
MAPK1 P28482 1/20 0.31
MAP2K4 P45985 1/20 0.31
MAPKAPK2 P49137 1/20 0.31
MAPKAPK3 Q16644 1/20 0.31
MAPK6 Q16659 1/20 0.31
MAPKAPK5 Q8IW41 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10189278 0.86 UGT1A1 (0.41) CFTRGAAMAPTSMN1; SMN2HSD17B10
SCHEMBL617870 0.86 ALDH1A1 (0.41) CFTRMAPTSMN1; SMN2HSD17B10ALDH1A1
SCHEMBL10189276 0.84 PTGS2 (0.32) MAPTSMN1; SMN2HSD17B10PTGS2PLG
SCHEMBL12339072 0.81 GAA (0.34) CFTRGAAMAPTTP53SMN1; SMN2
SCHEMBL10189277 0.80 PRKAB2 (0.32) MAPTSMN1; SMN2HSD17B10PTGS2ALDH1A1
SCHEMBL10189263 0.79 CYP2A6 (0.45)
SCHEMBL10189279 0.79 GRB2 (0.32) MAPTSMN1; SMN2HSD17B10PTGS2ALDH1A1
SCHEMBL10189280 0.78 NPC1 (0.32) RAB9A
SCHEMBL10189259 0.78 TUBB4A (0.36) MAPTALDH1A1LMNAHPGDNPSR1
SCHEMBL10189775 0.75 MAPT (0.34) CFTRGAAMAPTTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966172-B1 THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP (US) 2014-01-08 EP disclosed
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN (US) 2013-08-08 US disclosed
US-8399435-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-03-19 US disclosed
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 CFTR 1266/4885GAA 597/4885MAPT 95/4885
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 CFTR 1266/4885GAA 597/4885MAPT 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.